MNKT.Q Stock Overview
Mallinckrodt plc develops, manufactures, markets, and distributes specialty pharmaceutical products and therapies in the United States, Europe, the Middle East, Africa, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Mallinckrodt plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.12 |
| 52 Week High | US$12.15 |
| 52 Week Low | US$0.026 |
| Beta | 0 |
| 1 Month Change | 220.00% |
| 3 Month Change | -79.26% |
| 1 Year Change | -98.99% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -99.35% |
Recent News & Updates
Recent updates
Shareholder Returns
| MNKT.Q | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 33.3% | -2.7% | -2.1% |
| 1Y | -99.0% | 15.5% | 24.7% |
Rentabilidad frente al sector: MNKT.Q obtuvo unos resultados inferiores a los del sector US Pharmaceuticals , que el año pasado arrojó un rendimiento del -4.4%.
Rentabilidad vs. Mercado: MNKT.Q obtuvo unos resultados inferiores a los del mercado US, que fue del 15.2% el año pasado.
Price Volatility
| MNKT.Q volatility | |
|---|---|
| MNKT.Q Average Weekly Movement | 45.0% |
| Pharmaceuticals Industry Average Movement | 9.5% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.0% |
Precio estable de las acciones: MNKT.Qha sido volátil en los últimos 3 meses.
Volatilidad a lo largo del tiempo: MNKT.Qha disminuido de 77% a 45% en el último año, pero sigue siendo superior al 75% de los valores de US.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1867 | 2,687 | Siggi Olafsson | https://www.mallinckrodt.com |
Mallinckrodt plc Fundamentals Summary
| MNKT.Q fundamental statistics | |
|---|---|
| Market cap | US$936.02k |
| Earnings (TTM) | -US$2.97b |
| Revenue (TTM) | US$1.89b |
0.0x
P/S Ratio0.0x
P/E RatioIs MNKT.Q overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MNKT.Q income statement (TTM) | |
|---|---|
| Revenue | US$1.89b |
| Cost of Revenue | US$1.25b |
| Gross Profit | US$640.60m |
| Other Expenses | US$3.61b |
| Earnings | -US$2.97b |
Last Reported Earnings
Sep 29, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -222.21 |
| Gross Margin | 33.97% |
| Net Profit Margin | -157.55% |
| Debt/Equity Ratio | -34.4% |
How did MNKT.Q perform over the long term?
See historical performance and comparison